Recent retrospective and prospective studies on immune checkpoint inhibitors (ICIs) for GBM at Mount Sinai Hospital found that EGFR amplification was associated with worse survival outcomes for GBM patients treated with ICIs [22]. Here, EGFR is linked to glioblastoma.